n the last session of CTAD, Michela Gallagher of Johns Hopkins University, Baltimore, fired up a tired audience with news that a proprietary low-dose formulation of the atypical antiepileptic drug levetiracetam, called AGB101, was set to start a Phase 3 efficacy study in amnestic MCI in early 2016. Using an atypical anticonvulsant drug, this approach…
Baltimore, MD, November 24, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present on a panel at the Future of Innovation in Medicine Conference: Incentives for New Medical Treatments and Global Health next week. CEO Jerry McLaughlin will participate on a panel, entitled…
CEO Jerry McLaughlin will present as a “Top Project to Watch: Most Licensable Products in Neuroscience” on November 19 in Boston.
Could decelerating an overactive hippocampus halt Alzheimer’s disease in its tracks? Neuroscientist Michela Gallagher and her colleagues across the university aim to find out.
Baltimore, MD, November 11, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present as a “Top Project to Watch: Most Licensable Products in Neuroscience” at the Informa Therapeutic Area Partnering (TAP) conference, being held November 18 to 20 in Boston. CEO Jerry McLaughlin will present…
Clinical Trial in MCI Reducing Hippocampal Overactivity: HOPE4MCI AgeneBio’s Michela Gallagher and Sharon Rosenzweig-Lipson to present in Barcelona on Saturday, November 7, 2015, at 11:45 am
AGB101 formulation suitable for use in the upcoming HOPE4MCI Phase 3 clinical trial to slow the progression of aMCI, the symptomatic pre-dementia stage of Alzheimer’s disease Baltimore, MD, November 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced results of a crossover food effect study of its…